MARKET INTRODUCTION
Pharmacological agents which are used to reduce the body weight by losing the amount of cholesterol in body are called as Anti-obesity drugs. Anti-Obesity drugs alter the fundamental functions of human body by altering the appetite or by consuming the calories.
MARKET DYNAMICS
The Anti-Obesity Drugs market is anticipated to grow in the forecast period owing to driving factors such as adoption of sedentary lifestyle, increasing prevalence of obesity, introduction of novel anti-obesity drugs, chronic nature of disease, and increasing aging population.
MARKET SCOPE
The "Global Anti-Obesity Drugs Market Analysis to 2031" is a specialized and in-depth study of the medical device industry with a special focus on the global market trend analysis. The report aims to provide an overview of Anti-Obesity Drugs market with detailed market segmentation by drug class, medication, drug type, and geography. The global Anti-Obesity Drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Anti-Obesity Drugs market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global Anti-Obesity Drugs market is segmented on the basis of drug class, medication, and drug type. Based on drug class, the market is segmented into Peripherally Acting Anti-obesity Drugs, and Centrally Acting Anti-obesity Drugs. Based on medication, the market is segmented into Monotherapies and Polytherapies. Based on drug type, the market is segmented into Prescription Drugs and OTC Drugs.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Anti-Obesity Drugs market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Anti-Obesity Drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Anti-Obesity Drugs market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Anti-Obesity Drugs market in these regions.
MARKET PLAYERS
The reports cover key developments in the Anti-Obesity Drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Anti-Obesity Drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for Anti-Obesity Drugs market in the global market. Below mentioned is the list of few companies engaged in the Anti-Obesity Drugs market.
The report also includes the profiles of key Anti-Obesity Drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Arena Pharmaceuticals, Inc.
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline plc
- Alizyme plc
- Boehringer Ingelheim GmbH
- Novo Nordisk A/S
- Pfizer Inc
- Shionogi Inc.
- Merck and Co., Inc.
- Norgine B.V.
Anti-Obesity Drugs Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ XX Million |
| Market Size by 2031 | US$ XX Million |
| Global CAGR (2023 - 2031) | XX% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Drug Class
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Trends and growth analysis reports related to Life Sciences : READ MORE..
The List of Companies
1. Arena Pharmaceuticals, Inc.2. F. Hoffmann-La Roche Ltd3. GlaxoSmithKline plc4. Alizyme plc5. Boehringer Ingelheim GmbH6. Novo Nordisk A/S7. Pfizer Inc8. Shionogi Inc.9. Merck and Co., Inc.10. Norgine B.V.
1. Arena Pharmaceuticals, Inc.2. F. Hoffmann-La Roche Ltd3. GlaxoSmithKline plc4. Alizyme plc5. Boehringer Ingelheim GmbH6. Novo Nordisk A/S7. Pfizer Inc8. Shionogi Inc.9. Merck and Co., Inc.10. Norgine B.V.
Get Free Sample For